San­doz and Sam­sung Bioepis ink com­mer­cial­iza­tion agree­ment for Ste­lara biosim­i­lar

An­oth­er biosim­i­lar hope­ful for John­son & John­son’s Ste­lara is tak­ing steps to move to mar­ket as patent pro­tec­tions are set to end this year, this time in the form of a com­mer­cial­iza­tion agree­ment be­tween San­doz and Sam­sung Bioepis that was an­nounced to­day.

San­doz and Sam­sung’s biosim­i­lar is one of at least six that are be­ing de­vel­oped — de­spite that, Ste­lara was in­clud­ed on the ini­tial list of drugs that will be sub­ject to price ne­go­ti­a­tions be­gin­ning in 2026 un­der the In­fla­tion Re­duc­tion Act.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER